Dr. Bilsky had disclosed that he is on the advisory board for Varian Medical Systems, Inc., is on the cervical development team and a course instructor for Globus Medical Inc., and receives royalties from DePuy Synthes. Dr. Yamada has disclosed that he is a consultant for Varian Medical Systems, Inc. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network
Ms. Green has disclosed that she has no relevant financial relationships.
Deborah J. Moonan, RN, BSN, Director, Continuing Education, has disclosed that she has no relevant financial relationships.
Ann Gianola, MA, Manager, Continuing Education Accreditation & Program Operations, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Senior Manager, Clinical Content, has disclosed that she has no relevant financial relationships.
WoodwardEJagdevSMcParlandL. Skeletal complications and survival in renal cancer patients with bone metastases. Bone2011;48:160–166.
McKayRRKroegerNXieW. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol2014;65:577–584.
MotzerRJMazumdarMBacikJ. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol1999;17:2530–2540.
YamadaYBilskyMHLovelockDM. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys2008;71:484–490.
FlaniganRCMickischGSylvesterR. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol2004;171:1071–1076.
JuuselaHMalmioKAlfthanOOravistoKJ. Preoperative irradiation in the treatment of renal adenocarcinoma. Scand J Urol Nephrol1977;11:277–281.
KjaerMFrederiksenPLEngelholmS. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen renal cancer study group. Int J Radiat Oncol Biol Phys1987;13:665–672.
TunioMAHashmiARafiM. Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials. Ann Oncol2010;21:1839–1845.
WersällPJBlomgrenHLaxI. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol2005;77:88–95.
BeitlerJJMakaraDSilvermanPLedermanG. Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am J Clin Oncol2004;27:646–648.
SivaSPhamDGillS. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int2012;110:E737–743.
HartsellWFScottCBBrunerDW. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst2005;97:798–804.
NingSTrislerKWesselsBWKnoxSJ. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer1997;80(12 Suppl):2519–2528.
WalshLStanfieldJLChoLC. Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur Urol2006;50:795–800.
Haimovitz-FriedmanAKanCCEhleiterD. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med1994;180:525–535.
Garcia-BarrosMParisFCordon-CardoC. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science2003;300:1155–1159.
DiBiaseSJValicentiRKSchultzD. Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: support for dose escalation based on a biological model. J Urol1997;158:746–749.
BrennerDJ. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol2008;18:234–239.
KirkpatrickJPMeyerJJMarksLB. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol2008;18:240–243.
ParkCPapiezLZhangS. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys2008;70:847–852.
WrónskiMMaorMHDavisBJ. External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys1997;37:753–759.
GasparLScottCRotmanM. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys1997;37:745–751.
RadesDHeisterkampCSchildSE. Do patients receiving whole-brain radiotherapy for brain metastases from renal cell carcinoma benefit from escalation of the radiation dose?Int J Radiat Oncol Biol Phys2010;78:398–403.
CannadySBCavanaughKALeeSY. Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: a retrospective study. Int J Radiat Oncol Biol Phys2004;58:253–258.
KocherMSoffiettiRAbaciogluU. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol2011;29:134–141.
KondziolkaDPatelALunsfordLD. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys1999;45:427–434.
AndrewsDWScottCBSperdutoPW. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet2004;363:1665–1672.
BrownPDBrownCAPollockBE. Stereotactic radiosurgery for patients with “radioresistant” brain metastases. Neurosurgery2002;51:656–665.
GoyalLKSuhJHReddyCABarnettGH. The role of whole brain radiotherapy and stereotactic radiosurgery on brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys2000;47:1007–1012.
ManonRO'NeillAKniselyJ. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol2005;23:8870–8876.
YamadaYLovelockDMYeniceKM. Multifractionated image-guided and stereotactic intensity-modulated radiotherapy of paraspinal tumors: a preliminary report. Int J Radiat Oncol Biol Phys2005;62:53–61.
ChangELShiuASMendelE. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine2007;7:151–160.
ChowEDanjouxCWongR. Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists. Radiother Oncol2000;56:305–314.
CoxBWSprattDELovelockM. International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys2012;83:e597–605.
ZelefskyMJGrecoCMotzerR. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys2012;82:1744–1748.
GersztenPCBurtonSAOzhasogluCWelchWC. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976)2007;32:193–199.
GersztenPCBurtonSAOzhasogluC. Stereotactic radiosurgery for spinal metastases from renal cell carcinoma. J Neurosurg Spine2005;3:288–295.
NguyenQNShiuASRhinesLD. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys2010;76:1185–1192.
BalagamwalaEHAngelovLKoyfmanSA. Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma. J Neurosurg Spine2012;17:556–564.
WangXSRhinesLDShiuAS. A prospective analysis of the clinical effects of stereotactic body radiation therapy in cancer patients with spinal metastases without spinal cord compression. Lancet Oncol2012;13:395–402.
RyuSPughSLGersztenPC. RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases: phase 2 results. Pract Radiat Oncol2014;4:76–81.
SahgalAWhyneCMMaL. Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases. Lancet Oncol2013;14:e310–320.
BoehlingNSGrosshansDRAllenPK. Vertebral compression fracture risk after stereotactic body radiotherapy for spinal metastases. J Neurosurg Spine2012;16:379–386.
CunhaMVAl-OmairAAtenafuEG. Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT): analysis of predictive factors. Int J Radiat Oncol Biol Phys2012;84:e343–349.
RosePSLauferIBolandPJ. Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol2009;27:5075–5079.
MazeronRAndersonBSupiotS. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Cancer Treat Rev2011;37:476–486.
StaehlerMHasekeNNuhnP. Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. BJU Int2011;108:673–678.
TongCCKoECSungMW. Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS ONE2012;7:e36979.
KaoJPackerSVuHL. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases. Cancer2009;115:3571–3580.
SahgalALarsonDAChangEL. Stereotactic body radiosurgery for spinal metastases: a critical review. Int J Radiat Oncol Biol Phys2008;71:652–665.
LauferIIorgulescuJBChapmanT. Local disease control for spinal metastases following “separation surgery” and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J Neurosurg Spine2013;18:207–214.
SohnSChungCKSohnMJ. Stereotactic radiosurgery compared with external radiation therapy as a primary treatment in spine metastasis from renal cell carcinoma: a multicenter, matched-pair study. J Neurooncol2014;119:121–128.
ThibaultIAl-OmairAMasucciGL. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture. J Neurosurg Spine2014;21:711–718.